Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aloradine - Pherin Pharmaceuticals/VistaGen Therapeutics

Drug Profile

Aloradine - Pherin Pharmaceuticals/VistaGen Therapeutics

Alternative Names: Aloradine IN; Aloradine NS; PH94B; PH94B NS

Latest Information Update: 06 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Anxiolytics; Small molecules; Steroids
  • Mechanism of Action Chemoreceptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Social phobia

Most Recent Events

  • 23 Jul 2020 VistaGen Therapeutics announced the positive meeting with FDA regarding key aspects of pivotal phase III study for PH94B for the treatment of social anxiety disorder.
  • 29 Jun 2020 VistaGen Therapeutics plans a phase III follow up study for Social phobia, in 2020
  • 25 Jun 2020 Aloradine licensed to EverInsight Therapeutics in Greater China, South Korea and Southeast Asia for development and commercialisation for Social phobia
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top